Biosensors (B20.SG) has gained 1.9% at 79.5 cents in active trade as investors relook at stock after 8.2% fall since beginning March, reported Dow Jones Newswires.
Recent weakness triggered partly by concerns over heart stent maker’s distribution business in Germany following Medtronics’ acquisition of Invatec, an affiliate Krauth Cardiovascular, which distributes Biosensors’ flagship BioMatrix stent in Germany, one of Europe’s major stent markets.
